drugset / Trial / NCT02049606

To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee

NCT02049606 ↗

Phase 4 Completed 134 enrolled PMG Pharm Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet and CENATONE tablet in the treatment of osteoarthritis of the knee.

Timeline

Start
2014-02-24
Primary completion
2015-05-11
Completion
2016-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator CENATONE Unknown 500 mg —
Subject LAYLA Unknown 405.4 mg —

Indications